iRhythm Technologies, Inc. in the news

Federated Hermes and other institutional investors increased holdings in iRhythm Technologies, which reported strong revenue growth but a small loss, while analysts maintain a moderate buy rating.

iRhythm Technologies saw significant insider and institutional stock sales amid mostly positive analyst ratings and reported strong revenue growth despite negative earnings.

Needham raised iRhythm Technologies' price target to $254 and kept a buy rating, supported by multiple composite ratings and a BBB ESG score.

iRhythm Holdings exceeded Q4 revenue expectations and received positive analyst upgrades, highlighting strong growth prospects in digital cardiac monitoring.

Halper Sadeh LLC is urging iRhythm Technologies shareholders to contact them about possible fiduciary breaches and legal rights enforcement.

iRhythm Technologies is moderately favored by analysts with growing institutional interest and strong quarterly revenue growth, focusing on wearable cardiac monitoring solutions.

iRhythm Technologies led Q3 patient monitoring earnings with strong revenue growth and analyst beats amid sector-wide growth and challenges.

Stephens Investment Management reduced its stake in iRhythm Technologies amid generally positive analyst ratings and a Q3 earnings beat with revenue growth but ongoing losses.

Kuehn Law is investigating claims that iRhythm Technologies misled investors about the Zio AT monitor, causing inflated stock prices.

Halper Sadeh LLC is urging iRhythm Technologies shareholders to contact them regarding possible fiduciary breaches and potential legal remedies.

Analysts show bullish sentiment on Irhythm Technologies with a strong buy rating and significant upside potential, while Charles River Labs and Butterfly Network have mixed outlooks.

Halper Sadeh LLC is investigating potential fiduciary breaches by iRhythm Technologies' leadership and encourages shareholders to explore legal options for relief.

iRhythm Technologies raised 2025 revenue outlook but delayed Zio MCT launch to 2027, causing a 20% stock drop despite positive analyst outlook.

Wells Fargo and other analysts raised price targets for iRhythm Technologies, citing strong revenue growth and positive earnings despite recent stock price decline.

iRhythm reported strong 2025 financial results exceeding guidance, reinforced clinical evidence for its cardiac monitoring technology, and outlined growth plans for 2026 including market expansion and AI partnerships.

Wells Fargo and other analysts raised price targets for iRhythm Technologies, a digital health company specializing in wearable cardiac monitoring devices, signaling strong growth potential.

iRhythm Technologies received multiple analyst price target increases and a reaffirmed buy rating after strong Q3 results and growing institutional interest.

iRhythm Technologies expects 17-18% revenue growth in 2026, targeting $870-$880 million.

iRhythm Technologies reported strong 2025 financial results with record revenue and clinical validation of its cardiac monitoring solutions, projecting continued growth and market expansion in 2026.

iRhythm Technologies expects FY25 revenue to exceed its previous high-end guidance of $740 million.